Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mutant prion protein enhances NMDA receptor activity, activates PKC, and triggers rapid excitotoxicity in mice
Joie Lin, … , John R. Yates III, Christina J. Sigurdson
Joie Lin, … , John R. Yates III, Christina J. Sigurdson
Published April 4, 2025
Citation Information: J Clin Invest. 2025;135(10):e186432. https://doi.org/10.1172/JCI186432.
View: Text | PDF
Research Article Aging Neuroscience

Mutant prion protein enhances NMDA receptor activity, activates PKC, and triggers rapid excitotoxicity in mice

  • Text
  • PDF
Abstract

Neuronal hyperexcitability precedes synapse loss in certain neurodegenerative diseases, yet the synaptic membrane interactions and downstream signaling events remain unclear. The disordered amino terminus of the prion protein (PrPC) has been implicated in aberrant signaling in prion and Alzheimer’s disease. To disrupt neuronal interactions and signaling linked to the amino terminus, we CRISPR-engineered a knockin mouse expressing mutant PrPC (G92N), generating an N-linked glycosylation site between 2 functional motifs. Mice developed seizures and necrosis of hippocampal pyramidal neurons, similar to prion-infected mice and consistent with excitotoxicity. Phosphoproteomics analysis revealed phosphorylated glutamate receptors and calcium-sensitive kinases, including protein kinase C (PKC). Additionally, 92N-PrPC-expressing neurons showed persistent calcium influx as well as dendritic beading, which was rescued by an N-methyl-d-aspartate receptor (NMDAR) antagonist. Finally, survival of Prnp92N mice was prolonged by blocking active NMDAR channels. We propose that dysregulated PrPC-NMDAR–induced signaling can trigger an excitatory-inhibitory imbalance, spongiform degeneration, and neurotoxicity and that calcium dysregulation is central to PrPC-linked neurodegeneration.

Authors

Joie Lin, Julia A. Callender, Joshua E. Mayfield, Daniel B. McClatchy, Daniel Ojeda-Juárez, Mahsa Pourhamzeh, Katrin Soldau, Timothy D. Kurt, Garrett A. Danque, Helen Khuu, Josephina E. Ronson, Donald P. Pizzo, Yixing Du, Maxwell A. Gruber, Alejandro M. Sevillano, Jin Wang, Christina D. Orrú, Joy Chen, Gail Funk, Patricia Aguilar-Calvo, Brent D. Aulston, Subhojit Roy, Jong M. Rho, Jack D. Bui, Alexandra C. Newton, Stuart A. Lipton, Byron Caughey, Gentry N. Patrick, Kim Doré, John R. Yates III, Christina J. Sigurdson

×

Figure 1

Mice expressing Prnp92N develop rapidly progressive neurologic disease with necrosis of CA1 pyramidal neurons.

Options: View larger image (or click on image) Download as PowerPoint
Mice expressing Prnp92N develop rapidly progressive neurologic disease w...
(A) Schematic diagram of linear PrPC showing N- and C-terminal domains and the location of the G92N (red) or G92Q substitution (control, blue). The G92N substitution results in glycan incorporation into the flexible N-terminal domain. SP, signal peptide; OR, octapeptide repeat; SS, GPI signal sequence. The illustration in A was created with BioRender.com. (B) Western blot and quantification of PrPC expression and glycoform profile in Prnp92N mice (P18–P19). Tri, triglycosylated PrPC band; Di, diglycosylated PrPC band; Mono, monoglycosylated PrPC band; Un, unglycosylated PrPC band. (C) Survival curve for PrnpWT (n = 11), PrnpWT/92N (n = 16), Prnp92N/KO (n = 28), Prnp92N/92N (n = 18), and Prnp92Q (n = 26) mice. (D) Hind limb clasping in a Prnp92N mouse at P24 not observed in the littermate control or in a Prnp92Q mouse. (E) Graph showing the weight gain in mice from 7 to 25 days of age. (F) PrnpWT and Prnp92N (P25) hippocampi stained with H&E or immunolabeled for astrocytes (GFAP), microglia (Iba1), or myelin (MBP) and quantification of CA1. Arrowhead indicates the region where myelin is present in PrnpWT and reduced in the Prnp92N mice. (G) NeuN-immunolabeled hippocampi reveal extensive CA1 neuronal loss in Prnp92N mice (P29). (H) NeuN area quantified from hippocampi of P24 PrnpWT and Prnp92N mice. (I) H&E-stained images of Prnp92Nbrain show extensive perivascular neutrophils in the hippocampus (arrows, left panel) and multiple dark-rimmed and septate vacuoles in the brainstem (arrowheads, right panel) at P25, while images from prion-infected mice (strain ME7) also show neuron death in the hippocampus (arrows) and vacuoles in the brainstem (arrowheads). (J) MAP2 labeling of hippocampus shows a similar loss of dendrite structure in Prnp92N (P25) and in prion-infected mice, as compared with PrnpWT and mock-brain-inoculated control mice, respectively. (K) Representative TEM images of CA1 pyramidal neurons from age-matched PrnpWT and terminal Prnp92N mice. Arrow shows condensed chromatin. All results are shown as the mean ± SEM. One- or 2-way ANOVA with Tukey’s multiple-comparison test was performed to determine statistical significance (B, for PrPC levels and glycoform, respectively). The statistically significant differences were as follows: unglycosylated PrnpWT versus Prnp92N, ***P < 0.001 and versus PrnpWT/92N, *P < 0.05; monoglycosylated PrnpWT versus PrnpWT/92N, and versus Prnp92N, and PrnpWT/92N versus Prnp92N, ****P < 0.0001, ; diglycosylated PrnpWT versus PrnpWT/92N and Prnp92N, and PrnpWT/92N versus Prnp92N, ****P < 0.0001. Scale bars: 500 μm (F and G [left]), 50 μm (G [right], I, and J), and 5 μm and 2 μm (K, top and bottom, respectively).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts